BioToxTech Co Ltd

Capital Structure and Liquidity BioToxTech maintains a debt-to-equity ratio of 1.56, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.57, suggesting limited short-term liquidity to cover immediate liabilities. Despite a cash and equivalents balance of 18.63 billion KRW, the firm's long-term debt of 62.50 billion KRW results in a negative net cash position. ### Profitability and Returns The company's return on equity (ROE) is 2.9%, and return on assets (ROA) is 0.88%, both below the typical thresholds for strong performance in the healthcare services sector. Operating income is negative at -4.87 billion KRW, indicating operational inefficiencies or high costs relative to revenue. Gross profit of 5.88 billion KRW represents a 12.5% margin, which is relatively low for a research and evaluation services firm. ### Segments and Geographic Exposure BioToxTech operates in a single business segment focused on non-clinical evaluation services. The company's revenue is concentrated in the Korean market, with no disclosed international operations or revenue diversification. This concentration increases exposure to local economic and regulatory risks. ### Growth Trajectory The company's revenue for the latest period is 47.02 billion KRW. Analysts estimate a mean EBIT of 18.92 billion KRW, suggesting potential improvement in operating performance. However, the negative operating income and low ROE indicate challenges in achieving consistent growth. ### Risk Factors Key risk factors include liquidity constraints and the potential for dilution, although the latter is currently assessed as low. The company's capital structure is heavily leveraged, with long-term debt exceeding equity. This increases financial risk and limits flexibility in capital allocation. No recent dilutive events or significant changes in capital structure have been reported. ### Recent Events No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes. The company's recent performance remains primarily defined by its financial snapshot and analyst estimates.